SARS (Severe Acute Respiratory Syndrome)
Conditions
Keywords
colloidal silver, treatment, COVID-19
Brief summary
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I
Detailed description
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy. The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
Interventions
DRUGColloidal Silver
Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon) and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
DRUGPlacebo
Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Sponsors
Hôpital Universitaire Sahloul
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.
Exclusion criteria
* Any pregnant or breastfeeding woman * patient with an expectation of survival of less than 24 hours * Dyspnea leading to heart failure * Hepatic insufficiency * Chronic respiratory failure * Renal failure, clearance \<20ml • min-1 • 1.73 • m-²
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chage of clinical status | 10 DAYS | the distribution of clinical status assessed on the 7-point ordinal scale on day 10 of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | ON 1 month | adverse events throughout the study period |
| the duration of hospitalization | ON 11 days | number of days of hospitalization |
| the duration of the different respiratory assistance modes | ON 11 days | the duration of the different respiratory assistance modes |
| all-cause mortality | ON 1 month | the cause and the date of Death |
Countries
Tunisia
Contacts
Primary ContactBoukef Riadh, professor
Outcome results
None listed